THE SUBTYPES OF PANCREATIC DUCTAL ADENOCARCINOMAS
Being the 4th leading cause of cancer deaths in the U.S and with a global increase in incidence, above 80% of pancreatic cancers are locally advanced or metastatic at the time of diagnosis. As surgical resection is the only hope for a cure, the answer is probably in early screening, proper classification and right therapy. The advancing research will likely lead to a better understanding of Pancreatic Ductal Adenocarcinoma (PDAC) as well as enhance the techniques for screening, diagnosis, accurate subtyping and enable the use of targeted therapy. Thus, instead of clubbing together various subtypes of PDAC for trials, improving the subcategorization will ensure statistical significance for the academicians, and the clinicians would avoid administration of placebo drug to a vast number of patients
Wray CJ, Ahmad SA, Matthews JB, Lowy AM. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology. 2005;128(6):1626-41.
Mukherjee I, Powell B, Parianos M, Downs D, Ross SB. Available technologies and clinical applications of targeted chemotherapy in pancreatic cancer. Cancer Genetics. 2016 Aug 5.
Collisson EA, Sadanandam A, Olson P et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500-3.
Moffitt RA, Marayati R, Flate EL et al. Virtual microdissection identifies distinct tumor-and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47(10):1168-78.
Daemen A, Peterson D, Sahu N et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proc. Natl. Acad. Sci. 2015;112(32):E4410-7.
Bailey P, Chang DK, Nones K et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016; 531(7592):47–52.
Humphrey ES, Su SP, Nagrial AM et al. Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling. Mol. Cell. Proteomics. 2016;15 (8)2671–85.
Tanaka M, Chari S, Adsay V et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.. Pancreatology..2006; 6(1–2)17–32.
Tanaka M, Fernández-Del Castillo C, Adsay V et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183–97.
Saiki Y, Horii A. Molecular pathology of pancreatic cancer. Pathology international. 2014;64(1):10-9.
Fritz S, Fernandez-del Castillo C, Mino-Kenudson M et al. Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma.. Ann. Surg. 2009;249(3):440–7.
- There are currently no refbacks.
Copyright (c) 2016 authors
This work is licensed under a Creative Commons Attribution 4.0 International License.